Stock SWTX SPRINGWORKS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-12 pm EDT 		5-day change 1st Jan Change
41.44 USD +0.19% Intraday chart for SpringWorks Therapeutics, Inc. +12.70% +13.53%
Jul. 01 Sector Update: Health Care Stocks Mixed Premarket Monday MT
Jul. 01 Sector Update: Health Care MT

Summary

  • The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SPRINGWORKS THERAPEUTICS, INC. Stock SpringWorks Therapeutics, Inc.
+13.53% 3.07B
D+
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.12% 126B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+25.25% 119B
B+
ARGENX SE Stock argenx SE
+25.56% 27.95B
B
BIONTECH SE Stock BioNTech SE
-19.51% 20.5B
B+
GENMAB A/S Stock Genmab A/S
-14.36% 17.12B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.63% 16.1B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.67% 14.97B
A-
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.89% 14.84B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+57.74% 14.38B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SWTX Stock
  4. Ratings SpringWorks Therapeutics, Inc.